Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study
Morgan Birabaharan, Eddie Hill, Maedha Begur, David C. Kaelber, Thomas Martin, Sanjay R. Mehta
Abstract
Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavimab administration, including in patients with pre-existing cardiovascular disease.
Topics & Concepts
MedicinePropensity score matchingPost-hoc analysisCohortCohort studyPopulationDiseaseCoronavirusInternal medicineCoronavirus disease 2019 (COVID-19)Environmental healthInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesPharmaceutical studies and practices